News Medical on MSN22d
Rice bioengineers uncover why IL-12 immunotherapy loses effectiveness
A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) ⎯ a ...
Zacks Small Cap Research on MSN4d
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…
IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with ...
Imunon announces results from End-of-Phase 2 meeting with FDA for IMNN-001
IMUNON (IMNN) announced the outcome of its recent End-of-Phase 2 in-person meeting with the U.S. Food and Drug Administration, FDA, supporting ...
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...
clinicaladvisor.com15d
New Presentation, Indications Approved for Biosimilar Selarsdi
The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi â„¢ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...
Horse and Hound5d
Willberry Wonder Pony funds new research into rare cancer in young rider’s memory
Money by a Hannah’s Willberry Wonder Pony Charity, set up by the late young event rider Hannah Francis, will go towards ...
Science Daily24d
Bioengineers shed light on dosing challenges for cancer immunotherapy
A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) -- a potent immune-boosting protein that holds promise for cancer treatment ...